Table 1.
Immune checkpoint inhibitors in phase III and IV clinical trials
| Sl No | Drug | Cancer type | Clinical trial ID |
|---|---|---|---|
| 1 | Pembrolizumab (Anti-PD-1) | NSCLC | NCT03134456, NCT02220894, NCT02142738, NCT02864394, NCT03302234, NCT01905657, NCT02504372, NCT02775435, NCT02578680 |
| 2 | Small cell lung cancer | NCT03066778 | |
| 3 | Head and neck squamous cell carcinoma | NCT02252042, NCT03040999, NCT02358031 | |
| 4 | Renal cell carcinoma | NCT03142334, NCT02853331 | |
| 5 | Gastric adenocarcinoma | NCT02370498 | |
| 6 | Nasopharyngeal neoplasms | NCT02611960 | |
| 7 | Urothelial carcinoma | NCT02853305, NCT03244384, NCT02256436, NCT03374488, NCT03361865 | |
| 8 | Colorectal cancer | NCT02563002 | |
| 9 | Pleural mesothelioma | NCT02991482 | |
| 10 | TNBC | NCT02819518, NCT03036488, NCT02555657 | |
| 11 | Esophageal neoplasms | NCT03189719, NCT02564263 | |
| 12 | Multiple myeloma | NCT02579863, NCT02576977 | |
| 13 | Gastric and gastroesophageal junction cancer | NCT03019588, NCT03221426 | |
| 14 | Gastric adenocarcinoma | NCT02494583 | |
| 15 | Melanoma | NCT02362594, NCT01866319 | |
| 16 | Hodgkin lymphoma | NCT02684292 | |
| 17 | Hepatocellular carcinoma | NCT02702401, NCT03062358 | |
| 18 | Lung cancer | NCT03322540 | |
| 19 | Head and neck cancer | NCT03358472 | |
| 20 | Nivolumab (Anti-PD-1) | NSCLC | NCT02041533, NCT01642004, NCT01673867 |
| 21 | Mesothelioma | NCT03063450 | |
| 22 | Non-Hodgkin lymphoma | NCT03366272 | |
| 23 | Metastatic clear cell renal carcinoma | NCT01668784 | |
| 24 | Head and neck cancer | NCT02741570, NCT03342352 | |
| 25 | Lung cancer | NCT03348904 | |
| 26 | Melanoma | NCT03068455, NCT01844505 | |
| 27 | Ipilimumab (Anti-CTLA-4) | NSCLC | NCT03469960, NCT03351361, NCT02785952, NCT03302234 |
| 28 | Squamous cell lung carcinoma | NCT02785952 | |
| 29 | Mesothelioma | NCT02899299 | |
| 30 | Gastric cancer Gastroesophageal junction cancer |
NCT02872116 | |
| 31 | Metastatic melanoma | NCT03445533, NCT00636168, NCT01274338, NCT02339571, NCT02506153, NCT02224781, NCT00094653 | |
| 32 | Metastatic non-cutaneous melanoma | NCT02506153 | |
| 33 | Avelumab (Anti-PD-L1) | NSCLC | NCT02576574, NCT02395172 |
| 35 | Urothelial cancer | NCT02603432 | |
| 35 | Diffuse Large B-cell lymphoma | NCT02951156 | |
| 36 | Renal cell cancer | NCT02684006 | |
| 37 | Gastric and gastroesophageal junction cancer | NCT02625623, NCT02625610 | |
| 40 | Atezolizumab (Anti-PD-L1) | Ovarian cancer, fallopian tube cancer Peritoneal neoplasms |
NCT03038100, NCT02839707, NCT02891824 |
| 41 | NSCLC | NCT02813785, NCT02008227, NCT02367781, NCT02366143, NCT02409342, NCT02486718, NCT02367794, NCT03191786, NCT02409355, NCT02657434, NCT03456063 | |
| 42 | Extensive stage small cell lung cancer | NCT02763579 | |
| 43 | TNBC | NCT03197935, NCT02425891, NCT03125902, NCT03281954 | |
| 44 | Renal cell carcinoma | NCT02420821, NCT03024996 | |
| 45 | Bladder cancer | NCT02302807 | |
| 46 | Squamous cell carcinoma of the head and neck | NCT03452137 | |
| 47 | Urothelial carcinoma | NCT02807636 | |
| 48 | Transitional cell carcinoma | NCT02450331 | |
| 49 | Prostatic neoplasms | NCT03016312 | |
| 50 | Durvalumab (Anti-PD-L1) | NSCLC | NCT02352948, NCT03003962, NCT02453282, NCT02273375, NCT02542293, NCT03164616, NCT02125461, |
| 51 | Squamous cell lung carcinoma | NCT02154490, NCT02551159 | |
| 52 | Recurrent or metastatic PD-L1 positive or negative SCCHN | NCT02369874 | |
| 53 | Recurrent squamous cell lung caner | NCT02766335, NCT02154490 | |
| 54 | Urothelial cancer | NCT02516241 | |
| 55 | Advanced solid malignancies | NCT03084471 | |
| 56 | SCCHN, hypo pharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma | NCT02551159, NCT03258554 | |
| 57 | REGN2810 (Anti-PD-1) | NSCLC | NCT03409614, NCT03088540 |
| 58 | BMS-936558 (Anti-PD-1) | Unresectable or metastatic melanoma | NCT01721746, NCT01721772 |
| 59 | SHR1210 (Anti-PD-1) | NSCLC | NCT03134872 |
| 60 | Nasopharyngeal neoplasms | NCT03427827 | |
| 61 | KN035 (Anti-PD-L1) | Biliary tract neoplasms | NCT03478488 |
| 62 | IBI308 (Anti-PD-1) | Squamous cell lung carcinoma | NCT03150875 |
| 63 | PDR001 (Anti-PD-1) | Melanoma | NCT02967692 |
| 64 | Anti-PD-1 | Metastatic melanoma | NCT02821013 |
| 65 | BGB-A317 (Anti-PD-1) | NSCLC | NCT03358875 |
| 66 | Esophageal squamous cell carcinoma | NCT03430843 | |
| 67 | Hepatocellular carcinoma | NCT03412773 | |
| 68 | BCD-100 (Anti-PD-1) | NSCLC | NCT03288870 |
| 70 | JS001 (Anti-PD-1) | Metastatic melanoma | NCT03430297 |